AI-powered health intelligence firm GeneDx Holdings reported a notable insider sale as it advances its clinical data ...

The fair value price target for GeneDx Holdings sits at US$170.0, with the latest update keeping this headline target ...

GeneDx Holdings Corp WGS reported better-than-expected fourth-quarter financial results on Monday. GeneDx reported quarterly ...

GeneDx is upgraded to 'Buy' as valuation resets and operational improvements support a more realistic growth outlook. Learn ...

GeneDx Holdings Corp. (NASDAQ:WGS) reported mixed results for the fourth quarter, with earnings falling short of expectations ...

We reported quarterly revenues of $121,000,000, bringing full-year revenues to $428,000,000, underpinned by 54% exome and ...

Several pundits raised their price targets on the specialty healthcare company. This was hardly a surprise, as they came on the heels of an excellent earnings report. GeneDx's second-quarter earnings ...

Q4 2025 earnings call recap: revenue growth, 2026 guidance, margins, sales force expansion & reimbursement risks—read key insights now.

For full year 2026, GeneDx reaffirmed guidance of $540 million to $555 million in revenue, with the midpoint of $547.5 million slightly above the analyst consensus of $543 million. The company expects ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its launch on Aura, Epic’s specialty diagnostics ...